Search

Your search keyword '"Garside, J."' showing total 355 results
Start Over Author "Garside, J."
355 results on '"Garside, J."'

2. Dissemination of sport-based psychosocial interventions in Europe: results from the EASMH project

Author

Sampogna, G., primary, Borgi, M., additional, Cirulli, F., additional, Collacchi, B., additional, Cerino, S., additional, Di Tommaso, V., additional, Moliterni, S., additional, Bichi, A., additional, Barat, C., additional, Pringle, A., additional, Kivisto, S., additional, Melenco, I., additional, Oltean, A., additional, Garside, J., additional, and Fiorillo, A., additional

Published
2022
Full Text
View/download PDF

5. 750P PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial

Author

Slomovitz, B.M., Raaschou-Jensen, N., Coleman, R.L., Gilbert, L., Powell, M.A., Cibula, D., Ghamande, S., Zavallone, L., Mendivil, A.A., Ataseven, B., Black, D., Wymenga, M., Billingsley, C., Willmott, L.J., McCourt, C., Podzielinski, I., Doehring, O., Garside, J., Herzog, T.J., and Mirza, M.R.

Published
2023
Full Text
View/download PDF

6. 749P Patient-reported outcomes (PROs) in patients (pts) with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG3031/RUBY trial

Author

Valabrega, G., Powell, M.A., Hietanen, S., Miller, E.M., Novák, Z., Holloway, R., Denschlag, D., Myers, T., Thijs, A.M., Pennington, K., Gilbert, L., Fleming, E., Copeland, L., Gogoi, R., Podzielinski, I., Cloven, N., Meyers, O., Garside, J., Mirza, M.R., and Black, D.

Published
2023
Full Text
View/download PDF

9. Sport-based psychosocial interventions for people suffering from severe mental disorders: EASMH pilot actions from 4 European Countries.

Author

Di Vincenzo, M., Sampogna, G., Borgi, M., Collacchi, B., Cirulli, F., Cerino, S., Rullo, S., Luciano, M., Di Tommaso, V., Moliterni, S., Bichi, A., Garside, J., Kivistö, S., Iarion, A., Walker, M., and Fiorillo, A.

Abstract

Introduction: The European Alliance for Sport and Mental Health (EASMH) is a partnership of scientific institutions, charity associations and sport organizations, funded by EU-Erasmus+. It aimed at developing good clinical practice in psychiatric rehabilitation through sport-based interventions as an integration of pharmacological and psychological therapies. Within the framework of the EASMH projects, several actions have been promoted including an assessment of the dissemination of sport-based interventions, a training course for specialized coaches and the implementation of pilot actions in four European Countries. Objectives: To briefly describe EASMH pilot actions performed in Finland, Italy, Romania and United Kingdom, where trained coaches delivered sport-based interventions to patients with severe mental disorders. Methods: After completing pilot actions, charity associations and sport organizations belonging to EASMH network described general and specific aims, sport activities, composition of staff, timing and tools for assessing the outcomes. Results: In Italy, "Crazy for Rugby", including adolescents and young patients, and "Not only headshots", a football project for adults with severe mental disorders were performed. In UK, a football-based activity called "Imagine Your Goal" and a walking-football program for participants aged more than 40 were delivered. In Romania, two courses including gymnastics, yoga and pilates called "Get fit!" were provided. Different team sport-based activities were implemented in Finland, where "Multiple Sport Group" and "Rehabilitating Sports" aimed at increasing patients' autonomy. Assessment of psychopathological, social, cognitive and sport/fitness outcomes confirmed the overall beneficial effects of sport on mental health. Conclusions: Pilot actions represent the final step of EASMH project, which showed improvement of mental health outcomes by also delivering sport-based rehabilitation to patients with severe mental disorders. Institutions and stakeholders are now called to promote the implementation of such initiatives on a broader scale. Disclosure of Interest: None Declared [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Time to Switch to Second-line Antiretroviral Therapy in Children With Human Immunodeficiency Virus in Europe and Thailand

Author

Goetghebuer T, Hainaut M, Van der Kelen E, Delforge M, Warszawski J, Le Chenadec J, Ramos E, Dialla O, Wack T, Laurent C, Selmi L, Leymarie I, Benali F, Brossard M, Boufassa L, Floch-Tudal C, Firtion G, Hau I, Chace A, Bolot P, Blanche S, Granier M, Labrune P, Lachassine E, Dollfus C, Levine M, Fourcade C, Heller-Roussin B, Runel-Belliard C, Tricoire J, Monpoux F, Chirouze C, Reliquet V, Brouard J, Kebaili K, Fialaire P, Lalande M, Mazingue F, Partisani M, Koenigs C, Schultze-Strasser S, Baumann U, Niehues T, Neubert J, Kobbe R, Feiterna-Sperling C, Buchholz B, Notheis G, Spoulou V, Tovo P, Galli L, Chiappini E, Patrizia O, Larovere D, Ruggeri M, Faldella G, Baldi F, Badolato R, Montagnani C, Venturini E, Lisi C, Di Biagio A, Taramasso L, Giacomet V, Erba P, Esposito S, Lipreri R, Salvini F, Tagliabue C, Cellini M, Bruzzese E, Lo Vecchio A, Rampon O, Dona D, Romano A, Dodi I, Maccabruni A, Consolini R, Bernardi S, Genovese O, Olmeo P, Cristiano L, Mazza A, Garazzino S, Pellegatta A, Pajkrt D, Scherpbier H, Weijsenfeld A, van der Plas A, Jurriaans S, Back N, Zaaijer H, Berkhout B, Cornelissen M, Schinkel C, Wolthers K, Fraaij P, van Rossum A, van der Knaap L, Visser E, Boucher C, Koopmans M, van Kampen J, Pas S, Henriet S, de Flier M, van Aerde K, Strik-Albers R, Rahamat-Langendoen J, Stelma F, Scholvinck E, de Groot-de Jonge H, Niesters H, van Leer-Buter C, Knoester M, Bont L, Geelen S, Wolfs T, Nauta N, Ang C, van Houdt R, Pettersson A, Vandenbroucke-Grauls C, Reiss P, Bezemer D, van Sighem A, Smit C, Wit F, Boender T, Zaheri S, Hillebregt M, de Jong A, Bergsma D, Grivell S, Jansen A, Raethke M, Meijering R, de Groot L, van den Akker M, Bakker Y, Claessen E, El Berkaoui A, Koops J, Kruijne E, Lodewijk C, Munjishvili L, Peeck B, Ree C, Regtop R, Ruijs Y, Rutkens T, Schoorl M, Timmerman A, Tuijn E, Veenenberg L, van der Vliet S, Wisse A, Woudstra T, Tuk B, Marczynska M, Oldakowska A, Popielska J, Coupland U, Doroba M, Marques L, Teixeira C, Fernandes A, Prata F, Ene L, Gingaras C, Radoi R, Okhonskaia L, Voronin E, Miloenko M, Labutina S, Soler-Palacin P, Antoinette Frick M, Perez-Hoyos S, Mur A, Lopez N, Mendez M, Mayol L, Vallmanya T, Calavia O, Garcia L, Coll M, Pineda V, Rius N, Rovira N, Duenas J, Fortuny C, Noguera-Julian A, Jose Mellado M, Escosa L, Garcia Hortelano M, Sainz T, Isabel Gonzalez-Tome M, Rojo P, Blazquez D, Tomas Ramos J, Prieto L, Guillen S, Luisa Navarro M, Saavedra J, Santos M, Angeles Munoz M, Ruiz B, Fernandez Mc Phee C, Jimenez de Ory S, Alvarez S, Angel Roa M, Beceiro J, Martinez J, Badillo K, Apilanez M, Pocheville I, Garrote E, Colino E, Gomez Sirvent J, Garzon M, Roman V, Montesdeoca A, Mateo M, Jose Munoz M, Angulo R, Neth O, Falcon L, Terol P, Luis Santos J, Moreno D, Lendinez F, Grande A, Jose Romero F, Perez C, Lillo M, Losada B, Herranz M, Bustillo M, Guerrero C, Collado P, Antonio Couceiro J, Perez A, Isabel Piqueras A, Breton R, Segarra I, Gavilan C, Jareno E, Montesinos E, Dapena M, Alvarez C, Gloria Andres A, Marugan V, Ochoa C, Alfayate S, Isabel Menasalvas A, de Miguel E, Naver L, Soeria-Atmadja S, Hagas V, Aebi-Popp K, Asner S, Aubert V, Battegay M, Baumann M, Bernasconi E, Boni J, Brazzola P, Bucher H, Calmy A, Cavassini M, Ciuffi A, Duppenthaler A, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Francini K, Furrer H, Fux C, Grawe C, Gunthard H, Haerry D, Hasse B, Hirsch H, Hoffmann M, Hosli I, Kahlert C, Kaiser L, Keiser O, Klimkait T, Kovari H, Kouyos R, Ledergerber B, Martinetti G, de Tejada M, Metzner K, Muller, Nicca D, Paioni P, Pantaleo G, Polli C, Posfay-Barbe K, Rauch A, Rudin C, Schmid P, Scherrer A, Speck R, Tarr P, Lecompte T, Trkola A, Vernazza P, Wagner N, Wandeler G, Weber R, Wyler C, Yerly S, Techakunakorn P, Prachanukroh C, Hansudewechakul R, Wanchaitanawong V, Theansavettrakul S, Nanta S, Ngampiyaskul C, Phanomcheong S, Hongsiriwon S, Karnchanamayul W, Chacheongsao B, Kwanchaipanich R, Kanjanavanit S, Prapinklao S, Kamonpakorn N, Nantarukchaikul M, Adulyadej B, Layangool P, Mekmullica J, Lucksanapisitkul P, Watanayothin S, Lertpienthum N, Warachit B, Hanpinitsak S, Potchalongsin S, Thanasiri P, Krikajornkitti S, Attavinijtrakarn P, Srirojana S, Bunjongpak S, Puangsombat A, Na-Rajsima S, Ananpatharachai P, Akarathum N, Phuket V, Lawtongkum W, Kheunjan P, Suriyaboon T, Saipanya A, Than-in-at K, Jaisieng N, Suaysod R, Chailoet S, Naratee N, Kawilapat S, Kaleeva T, Baryshnikova Y, Soloha S, Bashkatova N, Raus I, Glutshenko O, Ruban Z, Prymak N, Kiseleva G, Bailey H, Lyall H, Butler K, Doerholt K, Foster C, Klein N, Menson E, Riordan A, Shingadia D, Tudor-Williams G, Tookey P, Welch S, Collins I, Cook C, Dobson D, Fairbrother K, Gibb D, Judd A, Harper L, Parrott F, Tostevin A, Van Looy N, Walsh A, Scott S, Vaughan Y, Laycock N, Bernatoniene J, Finn A, Hutchison L, Sharpe G, Williams A, Lyall E, Seery P, Lewis P, Miles K, Subramaniam B, Hutchinson L, Ward P, Sloper K, Gopal G, Doherty C, Hague R, Price V, Bamford A, Bundy H, Clapson M, Flynn J, Novelli V, Ainsley-Walker P, Tovey P, Gurtin D, Garside J, Fall A, Porter D, Segal S, Ball C, Hawkins S, Chetcuti P, Dowie M, Bandi S, McCabe A, Eisenhut M, Handforth J, Roy P, Flood T, Pickering A, Liebeschuetz S, Kavanagh C, Murphy C, Rowson K, Tan T, Daniels J, Lees Y, Kerr E, Thompson F, Le Provost M, Cliffe L, Smyth A, Stafford S, Freeman A, Reddy T, Fidler K, Christie S, Gordon A, Rogahn D, Harris S, Collinson A, Jones L, Offerman B, Van Someren V, Benson C, Riddell A, O'Connor R, Brown N, Ibberson L, Shackley F, Faust S, Hancock J, Donaghy S, Prime K, Sharland M, Storey S, Gorman S, Monrose C, Walters S, Cross R, Broomhall J, Scott D, Stroobant J, Bridgwood A, McMaster P, Evans J, Gardiner T, Jones R, Gardiner K, European Pregnancy Paediat HIV Coh, Stichting HIV Monitoring, Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Department of Sciences for Woman and Child's Health, Florence University, Dipartimento di Pediatria, Azienda Ospedaliera di Padova, Université Grenoble Alpes - UFR Pharmacie (UGA UFRP), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Pediatrics, and Virology

Subjects
Male, 0301 basic medicine, Time Factors, HIV, antiretroviral therapy, children, second-line, switch, [SDV]Life Sciences [q-bio], medicine.medical_treatment, Drug Resistance, INFANTS, HIV Infections, Cohort Studies, chemistry.chemical_compound, 0302 clinical medicine, Interquartile range, Antiretroviral Therapy, Highly Active, ADOLESCENTS, Cumulative incidence, Viral, Treatment Failure, 030212 general & internal medicine, Child, ComputingMilieux_MISCELLANEOUS, Antiretroviral therapy, Children, Second-line, Switch, Age Factors, Anti-HIV Agents, Child, Preschool, Drug Resistance, Viral, Drug Substitution, Europe, Female, Humans, Infant, Reverse Transcriptase Inhibitors, Thailand, Viral Load, Reverse-transcriptase inhibitor, Immunosuppression, OPEN-LABEL, VIROLOGICAL FAILURE, 3. Good health, Infectious Diseases, Viral load, medicine.drug, Microbiology (medical), medicine.medical_specialty, Efavirenz, Nevirapine, SCALE-UP, Article, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Internal medicine, medicine, Highly Active, Preschool, business.industry, HIV-1 DRUG-RESISTANCE, ADULTS, 030112 virology, RANDOMIZED-TRIAL, Regimen, INFECTED CHILDREN, VIRAL LOAD, chemistry, business
Abstract

Background. Data on durability of first-line antiretroviral therapy (ART) in children with human immunodeficiency virus (HIV) are limited. We assessed time to switch to second-line therapy in 16 European countries and Thailand.Methods. Children aged = 2 nucleoside reverse transcriptase inhibitors p[NRTIs] plus nonnucleoside reverse transcriptase inhibitor p[NNRTI] or boosted protease inhibitor p[PI]) were included. Switch to second-line was defined as (i) change across drug class (PI to NNRTI or vice versa) or within PI class plus change of >= 1 NRTI; (ii) change from single to dual PI; or (iii) addition of a new drug class. Cumulative incidence of switch was calculated with death and loss to follow-up as competing risks.Results. Of 3668 children included, median age at ART initiation was 6.1 (interquartile range (IQR), 1.7-10.5) years. Initial regimens were 32% PI based, 34% nevirapine (NVP) based, and 33% efavirenz based. Median duration of follow-up was 5.4 (IQR, 2.9-8.3) years. Cumulative incidence of switch at 5 years was 21% (95% confidence interval, 20%-23%), with significant regional variations. Median time to switch was 30 (IQR, 16-58) months; two-thirds of switches were related to treatment failure. In multivariable analysis, older age, severe immunosuppression and higher viral load (VL) at ART start, and NVP-based initial regimens were associated with increased risk of switch.Conclusions. One in 5 children switched to a second-line regimen by 5 years of ART, with two-thirds failure related. Advanced HIV, older age, and NVP-based regimens were associated with increased risk of switch.

Published
2017

14. A study of haemolytic streptococci, with special reference to their host distribution and fibrinolytic properties

Author

Garside, J. S.

Abstract

1. Three hundred and ninety-three strains of haemolytic streptococci from infective processes in animals were identified by means of Lancefield's precipitation test and their host association recorded. 2. 94.7 per cent. of haemolytic streptococci isolated from the horse were identified as group C, 72.2 per cent. of those from the cow belonged to group B, and 82 per cent. of strains from the dog proved to be group G. In both sheep and pigs the predominating group was group C, while the few strains obtained from cats all fell into group G. 3. These results, together with the findings recorded by previous workers, indicate the existence of a definite host -group relationship in these infections in animals as well as the recognised human-group A relationship. 4. The infrequency of generalised and suppurative streptococcal infections in cows, sheep, pigs and cats compared with the incidences observed in human beings, horses and dogs is commented upon. 5. The number of apparently normal dogs found to be carrying haemolytic streptococci in their throats was found to vary between thirty -four and sixty per cent.; the the public health aspect of this occurrence is noted. 6. The fibrinolysin production of one hundred and ninety-six of the above strains was investigated and it was determined that 42 per cent. of group C strains and. 14 per cent. of group G strains produced fibrinolysin. All members of groups B.E.F.K.L. & M were inactive, with the single exception of a group B strain. 7. The strains were tested against the fibrins of the horse, dog, cow, pig, sheep, and man, and of twenty - six active group C strains, twenty -three produced fibrinolysin, specific in action against horse's fibrin; two, a fibrinolysin specific against human fibrin, and one, a fibrinolysin specific against sheep's fibrin, while of thirteen active group C strains, nine were specific in action against human fibrin, three against horse's and human fibrin, and one against horse's fibrin alone. 8. The use of the fibrinolysin test. to detect potential human pathogens of group C as recommended by Sherman and Niven (1938) , and Hansen (1943) is confirmed and its adoption for the same purpose on strains of group C is advocated. 9. The test to determine the action of fibrnolysin on fibrinogen. is suggested as a more reliable means of detecting specific action of the enzyme than the use of preformed fibrin either from crude plasma or from fibrinogen thrombin mixtures. 10. The specificity of the fibrinolytic reaction is discussed, together with the production of autolysis and the possible relation of this reaction to the resistance of certain animal species to streptococcal infection. 11. Eighty -one strains of these streptococci were tested for evidence of the production of hyaluronidase by the method of Duran-Reynals. Ten per cent. were found to be active and included two group B strains and six group C strains. No members of group G were included amongst the active strains. 12. It is concluded from the results that fibrino-lysin and hyaluronidase, although produced by animal strains of haemolytic streptococci, are not important factors in the virulence of these organisms.

Published
1947

34. A CAM with mixed serial-parallel comparison for use in low energy caches

Author

Efthymiou, A. and Garside, J. D.

Subjects
asynchronous design, content-addressable memory, low-power design
Abstract

A novel, low-energy content addressable memory (CAM) structure is presented which achieves an approximately four-fold improvement in energy per access, compared to a standard parallel CAM, when used as tag storage for caches. It exploits the address patterns commonly found in application programs, where testing the four least significant bits of the tag is sufficient to determine over 90% of the tag mismatches; the proposed CAM checks those bits first and evaluates the remainder of the tag only if they match. Although, the energy savings come at the cost of a 25% increase in search time, the proposed CAM organization also supports a parallel operating mode without a speed loss but with reduced energy savings. Ieee Transactions on Very Large Scale Integration (Vlsi) Systems

Published
2004

35. The Science Case for 4GLS

Author

Allan, R.J., Allen, M.P., Alexandrov, A.S., Ashfold, M.N.R., Atkinson, R., Avaldi, L., Bain, C.D., Bancroft, J., Barrett, S.D., Barron, L.D., Bayliss, S., Becker, U., Benning, L.G., Berrah, N., Binns, C., Bisby, R.H., Bizau, J.M., Blake, R.J., Bowler, M.A., Bowyer, J., Brettle, J., Briggs, D., Brown, L.M., Brown, W.A., Burke, P.G., Cacho, C., Carter, R., Catlow, R., Cernik, R.J., Chesters, M., Clark, S.A., Clarke, D.T., Clarke, J.A., Codling, K., Cogdell, R., Connaughton, D., Connerade, J.P., Costello, J.T., Crapper, M.D., Creaser, C., Currell, F.J., Davies, P.B., de Jong, M., Dessent, C., Dhanak, V.R., Dobson, D.M., Dobson, P.J., Doig, A.J., Donovan, R.J., Dumas, P., Dunn, K., Dutuit, O., Dyke, J.M., Eastham, D.A., Egdell, R.G., Eland, J.H.D., Emerson, D.R., Eriksson, M., Erman, P., Evans, A., Evans, H., Evans, S., Field, T., Fielding, H., Fisher, A., Flavell, W.R., Ford, R., Frasinski, L.J., Freeman, N., Galayda, J.N., Gardner, P., Garside, J., Gay, N.J., Gejo, T., George, M., Gray, M.D., Greenshaw, T.J., Greig, D., Halsall, M.P., Hamilton, B., Harrison, N.M., Hasnain, S.S., Hatherly, P.A., Heathcote, P., Helliwell, J.R., Henderson, C.M.B, Hepburn, J., Hill, J., Hirst, G., Hirst, J.D., Holland, D.M.P., Horn, A.B., Horton, P., Hunt, M.R.C., Hutchinson, H., Inglesfield, J.E., Ivanov, V.K., Johnson, C.A.F., Johnson, L.N., Jones, D., Jones, F.H., Jones, G.R., Jones, L., Kadodwala, M., Karlsson, L., Kennedy, E.T., King, G.C., King, M.R.F., Kirkman, I.W., Kleese, K., Knight, P.L., Kylstra, N., Larkins, F.P., Latimer, C., Lawley, K.P., Leggett, G.J., Lewis, R.A., Lindsey, K., Lu, J.R., Lyng, F.M., Macdonald, M.A., Malins, A., Marangos, J.P., Margaritondo, G., Marsi, M., Marston, G., Martin, S.R., Martin-Fernandez, M.L., Mason, N.J., Matthew, J.A.D., McCoustra, M.R.S., McGilp, J., McGovern, I.T., McGrath, R., Meldrum, R.A., Meyer, M., Millar, T.J., Mitchell, D., Møller, S.P., Molster, F.J., Moriarty, P., Morin, P., Munro, I.H., Murdin, B.N., Nahon, L., Newell, W.R., Noble, C.J., Nordgren, E.J., Norman, P.R., O'Brien, P., O'Neill, P., O'Shea, P., Owen, H., Pain, R., Papiz, M., Parker, A., Parker, J., Parr, A., Pattrick, R., Pemble, M.E., Picardo, M., Pidgeon, C.R., Pinheiro, T.J.T., Poliakoff, E.D., Poole, M.W., Potts, A., Potvliege, R., Powis, I., Price, S.D., Quinn, F.M., Radford, S., Rachlew-Källne, E., Raval, R., Read, F.H., Reddish, T.J., Ridley, P.A., Roberts, G., Russell, A.E., Ryan, A.J., Sapelkin, A., Sato, S., Schneider, A., Seddon, E.A., Shaw, E.A., Shen, T., Sherwood, P., Šiller, L., Smith, A.D., Smith, D.A., Smith, I., Smith, S.L., Snowdon, K., Softley, T.P., Sokell, E., Southworth, S.H., Srivistava, G.P., Stankiewicz, M., Sule-Suso, J., Sutherland, J.C., Surman, M., Svensson, S., Taylor, A.O., Temmerman, W.M., Thomas, A., Tiddy, G.J., Tobin, M., Towns-Andrews, Elizabeth, Towrie, M., Truscott, G., Tuckett, R.P., Turner, Tracy, Twigg, M.V., Vagdama, P., van der Hart, H.W., Volk, M., Vrakkring, M.J.J., Walker, I.C., Wander, A., Wasserman, S.P., Watanabe, M., Weightman, P., Welton, T., West, J.B., Wharton, C.W., Whitehead, J.C., Williams, G.P., Winick, H., Withnall, R., Woodruff, D.P., and Zayats, A.

Subjects
Q1
Published
2001

40. Improve Separations!

Author

Krishna, R., Wesselingh, J.A., Garside, J., and Chemical Reactor engineering (HIMS, FNWI)

Published
1994

Catalog

Books, media, physical & digital resources
See catalog results